Emilie Breeding
Psychiatric/Mental Health · Miamisburg, OHNPI 1174077333
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,125 of the $39,776 with a category attached, or 68.2%. AbbVie accounts for 68.0% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $15,963, more than ten times the $499 reported in 2021. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $74.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$27K
- Neos Therapeutics, LP$3K
- Aytu Biopharma, Inc.$2K
- Axsome Therapeutics, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$601
- plus $5K from 21 others
What the payments were for
- Speaking & faculty fees$27,12568%
- Travel & lodging$1,5964%
- Food & beverage$11,05128%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 150 | $27,044 |
| Neos Therapeutics, LP | 54 | $3,303 |
| Aytu Biopharma, Inc. | 3 | $1,650 |
| Axsome Therapeutics, Inc. | 49 | $1,470 |
| Otsuka America Pharmaceutical, Inc. | 48 | $1,202 |
| Johnson & Johnson | 32 | $601 |
| Supernus Pharmaceuticals, Inc. | 19 | $581 |
| Neurocrine Biosciences, Inc. | 21 | $564 |
| Alkermes, Inc. | 20 | $510 |
| Teva Pharmaceuticals USA, Inc. | 13 | $441 |
| Lundbeck LLC | 26 | $438 |
| Corium, LLC | 25 | $371 |
| Ironshore Pharmaceuticals Inc. | 12 | $333 |
| Almatica Pharma LLC | 10 | $250 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $234 |
| Vanda Pharmaceuticals Inc. | 9 | $183 |
| Tris Pharma Inc | 9 | $151 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Noven Therapeutics, LLC | 4 | $68 |
| Collegium Pharmaceutical, Inc. | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Indivior Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Tempus AI, Inc | 1 | $14 |
| Biogen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$25,048
- Cotempla XR-ODT$2,725
- Adzenys XR-ODT$2,075
- LYBALVI$885
- EXXUA$700
- REXULTI$364
- Auvelity$357
- INGREZZA$245
- QELBREE$224
- JORNAY PM$133
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- AUSTEDO$125
- COBENFY$124
- Austedo XR$123
How this compares
$39,776 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 38 | $27,174 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,377 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 21 | $3,173 |
| Bupropion XlBupropion Hcl | 35 | $2,369 |
| Aripiprazole | 28 | $1,639 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 60 | $1,439 |
| Fluoxetine Hcl | 18 | $1,366 |
| Duloxetine Hcl | 49 | $1,041 |
| Clonazepam | 37 | $387 |
| Lamotrigine | 11 | $233 |
| Sertraline Hcl | 21 | $222 |
| Citalopram HbrCitalopram Hydrobromide | 64 | $220 |
| Trazodone Hcl | 51 | $214 |
| Lorazepam | 30 | $181 |
| Lithium Carbonate ErLithium Carbonate | 12 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $27,044 | $27,17438 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $88 | $5,37712 claims |
| Almatica Pharma LLCSertraline Hcl | $250 | $22221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Miamisburg
- Ashley GouldMiamisburg$10K
- Joshua TindallMiamisburg$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.